Leukaemia Section
Short Communication

t(4;12)(q11-q21;p13)
Jean-Loup Huret, Marina Lafage-Pochitaloff

Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France (JLH); Laboratoire de Cytogénétique Hématologique, Institut Paoli-Calmettes, Marseille, France (MLP)

Published in Atlas Database: January 1998
Online version is available at: http://AtlasGeneticsOncology.org/Anomalies/t0412.html
DOI: 10.4267/2042/32106

This work is licensed under a Creative Commons Attribution-Non commercial-No Derivative Works 2.0 France Licence.
© 1998 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Identity

Note: it is likely that breakpoints are heterogeneous, with 2 distinct entities: t(4;12)(q11-12;p13) in ANLL, and t(4;12)(q13-21;p13) in ALL to be delineated.

Clinics and pathology

Disease
ANLL and therapy related AL cases with t(4;12)(q11-12;p13); B-cell ALL cases seem to have a more distal breakpoint in 4q13 or 21.

Phenotype / cell stem origin
ANLL cases: M0, M1, and other subtypes; often CD7+; a stem cell may be involved; ALL cases are CD10+.

Epidemiology
Only 13 available cases: 9 ANLL and 4 ALL; so far, ANLL cases with a proximal breakpoint in 4q11 or 12 are adult cases (43-77 yrs), and ALL cases are children cases (3-14 yrs); balanced sex ratio.

Prognosis
Adult cases: response to therapy is poor and median survival might be a year.

Cytogenetics

Additional anomalies
None in 5/12 cases (all 5 cases are ANLL); del(6q) has recurrently been found in ALL; -7 would be recurrent if only 1 entity exists; the karyotype in ALL cases can be complex.

Genes involved and Proteins

ETV6
Location: 12p13
DNA / RNA
9 exons; alternate splicing.

Protein
Contains a Helix-Loop-Helix and ETS DNA binding domains; wide expression; nuclear localisation; ETS-related transcription factor.

References


This article should be referenced as such: